drugset / Trial / NCT00189475
Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds
RandomizedParallel-groupTriple-blindPrevention
Summary
Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.
Timeline
- Start
- 2003-10
- Primary completion
- 2007-07
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Montelukast | Other / unclassified | 4 mg | Oral |
| Comparator | Montelukast | Other / unclassified | 10 mg | Oral |